Bulletin
Investor Alert

New York Markets Open in:

Market Snapshot Analyst Ratings

Cabaletta Bio Inc.

NAS: CABA

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Cabaletta Bio Inc.

After Hours

 --Quotes are delayed by 20 min

Aug 8, 2022, 7:44 p.m.

CABA
/zigman2/quotes/214676209/composite

$

1.26

Change

+0.01 +0.80%

Volume

Volume 1,437

Quotes are delayed by 20 min

/zigman2/quotes/214676209/composite

Previous close

$ 1.33

$ 1.25

Change

-0.08 -6.02%

Day low

Day high

$1.21

$1.38

Open

52 week low

52 week high

$0.90

$14.95

Open

Company Description

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells ...

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Valuation

Price to Book Ratio

0.93

Enterprise Value to EBITDA

1.84

Efficiency

Liquidity

Current Ratio

14.86

Quick Ratio

14.86

Cash Ratio

14.59

Profitability

Return on Assets

-38.40

Return on Equity

-40.69

Return on Total Capital

-40.71

Capital Structure

Officers and Executives

Name Age Officer Since Title
Dr. Steven Nichtberger 59 2017 Chairman, President & Chief Executive Officer
Mr. Anup Marda 41 2019 CFO & Principal Accounting Officer
Dr. Gwendolyn Binder-Scholl 45 2019 Executive Vice President-Science & Technology
Dr. David J. Chang 56 2019 Chief Medical Officer
Dr. Samik Basu - 2019 VP-Preclinical Research & Translational Medicine

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/31/2022 Steven Nichtberger
President & CEO; Director 		50,000   Derivative/Non-derivative trans. at $1.01 per share. 50,500
11/01/2021 5AM Venture Management LLC
36,544   Disposition at $13 per share. 475,072
11/01/2021 5AM Venture Management LLC
258,456   Disposition at $13 per share. 3,359,928
09/07/2021 5AM Venture Management LLC
625,000   Disposition at $9.7 per share. 6,062,500
01/12/2021 5AM Venture Management LLC
10,530   Disposition at $13 per share. 136,890
01/12/2021 5AM Venture Management LLC
74,470   Disposition at $13 per share. 968,110
01/08/2021 5AM Venture Management LLC
37,411   Disposition at $13 per share. 486,343
01/08/2021 5AM Venture Management LLC
264,589   Disposition at $13 per share. 3,439,657
12/10/2020 5AM Venture Management LLC
36,916   Disposition at $14.75 per share. 544,511
12/10/2020 5AM Venture Management LLC
261,084   Disposition at $14.75 per share. 3,850,989
10/29/2019 5AM Venture Management LLC
454,545   Acquisition at $11 per share. 4,999,995
10/29/2019 Deerfield Management Company LP
700,000   Acquisition at $11 per share. 7,700,000
10/29/2019 5AM Venture Management LLC
3,214,721   Derivative/Non-derivative trans. at $0 per share. 0
10/29/2019 Deerfield Management Company LP
464,253   Derivative/Non-derivative trans. at $0 per share. 0
10/29/2019 Deerfield Management Company LP
464,253   Derivative/Non-derivative trans. at $0 per share. 0
10/29/2019 Steven Nichtberger
President & CEO; Director 		60,483   Derivative/Non-derivative trans. at $0 per share. 0
10/29/2019 Redmile Group LLC
696,378   Derivative/Non-derivative trans. at $0 per share. 0
10/29/2019 Mark Simon
Director 		18,144   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/caba

MarketWatch News on CABA

  1. Cabaletta Bio stock price target cut to $10 from $20 at Mizuho

    6:57 a.m. May 25, 2022

    - Tomi Kilgore

  3. Cabaletta Bio initiated at buy with $21 price target at Chardan Research

    9:20 a.m. Jan. 8, 2021

    - Tonya Garcia

  4. Cabaletta Bio started at outperform with $25 stock price target at Evercore ISI

    8:40 a.m. Nov. 19, 2019

    - Tomi Kilgore

  6. Cabaletta Bio shares slide 17.6% in trading debut

    12:28 p.m. Oct. 25, 2019

    - Ciara Linnane

/news/nonmarketwatch/company/us/caba

Other News on CABA

  1. What Makes Cabaletta Bio, Inc. (CABA) a New Buy Stock

    12:00 p.m. June 9, 2022

    - Zacks.com

  2. Cabaletta Bio (CABA) Investor Presentation - Slideshow

    12:24 p.m. May 27, 2022

    - Seeking Alpha

  3. Cabaletta Bio updates Phase 1 interim data for lead asset

    12:18 p.m. May 18, 2022

    - Seeking Alpha

  4. EDRY, WKEY and HPK among mid-day movers

    12:55 p.m. April 25, 2022

    - Seeking Alpha

  5. Cabaletta Bio (CABA) Investor Presentation - Slideshow

    12:13 p.m. April 14, 2022

    - Seeking Alpha

  6. 10-K: CABALETTA BIO, INC.

    8:28 a.m. March 17, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  8. RIOT, MARA and HIVE among pre market gainers

    9:46 a.m. March 1, 2022

    - Seeking Alpha

  9. The Carnage Under The Surface Of The Stock Market

    2:51 a.m. Jan. 25, 2022

    - Seeking Alpha

  11. Wall Street Breakfast: What Moved Markets

    9:39 a.m. Dec. 18, 2021

    - Seeking Alpha

  13. NES, LNDC and AVCT among mid-day movers

    1:27 p.m. Dec. 14, 2021

    - Seeking Alpha

  18. 10-Q: CABALETTA BIO, INC.

    7:39 a.m. Nov. 1, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  19. Cabaletta Bio EPS beats by $0.05

    7:24 a.m. Nov. 1, 2021

    - Seeking Alpha

  20. Cabaletta Bio (CABA) Investor Presentation - Slideshow

    2:50 p.m. Sept. 10, 2021

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Cabaletta Bio, Inc.

2929 Arch Street

Suite 600

Philadelphia, Pennsylvania 19104

Phone

1 2677593100

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

View SEC Filings

Revenue

N/A

Net Income

$-46.29M

Employees

54.00

Annual Report for CABA

/news/pressrelease/company/us/caba

Press Releases on CABA

  21. Loading more headlines...
Link to MarketWatch's Slice.